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 Use of a dialysis catheter rather than an 
arteriovenous fi stula is associated with 
higher dialysis patient mortality. Higher 
rates of infection account for part of this 
eff ect. Infl ammation could play an addi-
tional role. 
 Goldstein  et al. 1 (this issue) report that 
a change of dialysis access from a catheter 
to a fi stula is accompanied by a signifi cant 
fall in the serum level of C-reactive pro-
tein (CRP), and reduction of infl amma-
tion. Th ese fi ndings were in patients who 
did not have evident catheter infections. 
Th is should provide yet further impetus 
to use fi stulas rather than catheters in our 
hemodialysis patients. 
 Some issues remain, however. Th e fi rst 
is that in this report, information on long-
term outcome is not provided, either for 
morbidity and mortality or for quality of 
life. One can assume that a fall in the CRP 
level is a good thing, and that such a drop 
may reduce cardiovascular morbidity and 
mortality, but assumption is not fact. A 
second point is that other markers of 
infl ammation, such as the white blood cell 
count, were not reported, even though the 
latter is a long-established correlate of 
 cardiovascular pathology. 2 A fi nal concern 
is that there can be substantial variation in 
the CRP level in a given patient, and single 
values of CRP were used by Goldstein 
 et al. , 1 rather than multiple ones. Still, the 
patterns of change in CRP levels are dis-
tinct and diff er between those who got a 
fi stula and those who remained with a 
dialysis catheter. 
 Catheters are to be avoided, then, not 
just because they are associated with 
worse outcomes, but now also because 
they are a proinfl ammatory stimulus, 
perhaps contributing by that mechanism 
to their association with greater mortal-
ity. To fi rm up this mechanistic link, one 
should ask two questions. First, is 
infl ammation mechanistically important 
in aff ecting morbidity and mortality in 
nonrenal disease? Second, are there 
experimental data to support this link? 
Th ere is a known surfeit of cardiovascu-
lar mortality in subjects with rheuma-
toid arthritis, an obvious infl ammatory 
condition. 3 Also, a lipopolysaccharide 
model of chronic infl ammation in rats 
caused them to have cardiac fi brosis and 
microvascular injury. 4 But it is not estab-
lished that this occurs via CRP. The 
mechanistic role of CRP can be tested by 
mendelian randomization. Th is tech-
nique identifi es subjects with genetically 
determined diff erences in a particular 
trait and tests whether the putative eff ect 
of that trait indeed corresponds to the 
genetically determined diff erences. For 
subjects with metabolic syndrome, 
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 Hemodialysis patients have greater morbidity and mortality when they 
have a catheter rather than an arteriovenous fistula access. Catheter 
infection plays a significant role in this effect. Inflammation associated 
with dialysis catheter use could have an independent adverse effect on 
patient outcomes. Awareness and further study of the role of 
inflammation are needed. 
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genetic variation in CRP did not aff ect 
cardiovascular outcomes. 5 
 Th ere are further practical limits. First, 
there probably is a limit to our ability to 
reduce mortality in subjects with end-
stage renal disease. Go  et al. show clearly 
the 15 % yearly mortality of subjects with 
chronic renal failure who are not (yet) 
on dialysis. 6 It is hard to imagine that we 
will be able to reduce the yearly mortal-
ity of people on dialysis to a lesser per-
centage than those 15 % . Second, 
although it is a laudable goal to reduce 
catheter use, clinician nephrologists 
know that this is oft en not possible. Vas-
cular arteriovenous access may be 
impossible, for instance because of bad 
vascular disease. So, too, may some 
patients refuse to have an arteriovenous 
fi stula created. Th ey prefer the painless 
access of a catheter, and they do not 
make the connection between worse 
outcomes and catheters, in part because 
those outcomes occur in the hospital and 
are not visible to them in the outpatient 
dialysis unit. In future studies compar-
ing catheters with fi stulas, it could be 
informative to test quality of life, using 
tools such as the SF-36 health survey. 
 Nonetheless, it is rational to pay atten-
tion to markers of morbidity and future 
mortality. When the CRP level is above 
3  mg / l, a dialysis patient may have an 
adverse outcome (Figure 1). Th is may be 
recognized clinically by a poor appetite, 
or by the presence of itching. 7,8 Creating 
a fi stula should avoid the acknowledged 
adverse eff ects of a catheter — infection, 
clotting, underdialysis — and could also 
reduce the infl ammatory CRP. If that 
switch in access cannot be made, there 
may be other measures that may reduce 
the CRP. The recent JUPITER study 
reported a benefit of rosuvastatin to 
reduce the low-density lipoprotein cho-
lesterol and the CRP in subjects without 
kidney disease, but statins have been 
tested in dialysis patients and do not 
improve survival. 9,10 If lowering of the 
CRP is still wanted, one can consider 
treatment for periodontal disease, a 
Mediterranean diet, and the tasty option 
of eating dark chocolate. 11 – 13 
 One must also consider whether lowering 
the blood CRP level is always a good thing, 
and whether an elevated CRP may have some 
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good associated with it. Th e CRP molecule 
has existed for  hundreds of millions of years. 
It is a pentamer exported from the liver and 
is part of our innate immunity. It assists in 
bacterial killing, for instance, via complement 
and via opsonization. It may also assist in 
eliminating apoptotic and necrotic tissue. 14 
Long-term studies of CRP need to watch for 
any adverse eff ects of hobbling this innate 
defense. 
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 Figure 1  |  Kaplan – Meier estimate of survival in hemodialysis patients with serum C-reactive 
protein (CRP) levels in the highest quartile, middle two quartiles, and lowest quartile. 
 * P  =  0.0015 vs CRP   <  2.6   g / ml;  * * P  =  0.0090 vs CRP   <  2.6   g / ml;   †  P  =  0.0028 vs CRP 2. 6 – 5.2   g / ml; 
  ‡  P  =  0.0012 vs CRP   <  5.3 – 11.5   g / ml;   §  P  =  0.0001 vs CRP   <  2.6   g / ml. (Adapted with permission 
from ref.  15 .) 
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